Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer

Shama Prasada Kabekkodu; Sanjiban Chakrabarty; Supriti Ghosh; Angela Brand; Kapaettu Satyamoorthy

doi:10.1159/000475804

Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer

Shama Prasada Kabekkodu, Sanjiban Chakrabarty, Supriti Ghosh, Angela Brand, Kapaettu Satyamoorthy^*

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer. (C) 2017 S. Karger AG, Basel

Original language	English
Pages (from-to)	100-115
Number of pages	16
Journal	Public Health Genomics
Volume	20
Issue number	2
DOIs	https://doi.org/10.1159/000475804
Publication status	Published - 2017

Keywords

Cervical cancer
Epigenetics
Risk factors
Personalized medicine
POTENTIAL PROGNOSTIC MARKER
PAPILLOMAVIRUS TYPE-16 DNA
SQUAMOUS-CELL CARCINOMA
INTRAEPITHELIAL NEOPLASIA
TUMOR-SUPPRESSOR
DOWN-REGULATION
ABERRANT METHYLATION
EPIGENETIC MECHANISM
PROMOTER METHYLATION
SOCIOECONOMIC-STATUS

Access to Document

10.1159/000475804

Cite this

@article{58989effae6b4d4cb59947d52fcefb5d,

title = "Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer",

abstract = "Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer. (C) 2017 S. Karger AG, Basel",

keywords = "Cervical cancer, Epigenetics, Risk factors, Personalized medicine, POTENTIAL PROGNOSTIC MARKER, PAPILLOMAVIRUS TYPE-16 DNA, SQUAMOUS-CELL CARCINOMA, INTRAEPITHELIAL NEOPLASIA, TUMOR-SUPPRESSOR, DOWN-REGULATION, ABERRANT METHYLATION, EPIGENETIC MECHANISM, PROMOTER METHYLATION, SOCIOECONOMIC-STATUS",

author = "Kabekkodu, {Shama Prasada} and Sanjiban Chakrabarty and Supriti Ghosh and Angela Brand and Kapaettu Satyamoorthy",

year = "2017",

doi = "10.1159/000475804",

language = "English",

volume = "20",

pages = "100--115",

journal = "Public Health Genomics",

issn = "1662-4246",

publisher = "Karger",

number = "2",

}

TY - JOUR

T1 - Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer

AU - Kabekkodu, Shama Prasada

AU - Chakrabarty, Sanjiban

AU - Ghosh, Supriti

AU - Brand, Angela

AU - Satyamoorthy, Kapaettu

PY - 2017

Y1 - 2017

N2 - Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer. (C) 2017 S. Karger AG, Basel

AB - Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer. (C) 2017 S. Karger AG, Basel

KW - Cervical cancer

KW - Epigenetics

KW - Risk factors

KW - Personalized medicine

KW - POTENTIAL PROGNOSTIC MARKER

KW - PAPILLOMAVIRUS TYPE-16 DNA

KW - SQUAMOUS-CELL CARCINOMA

KW - INTRAEPITHELIAL NEOPLASIA

KW - TUMOR-SUPPRESSOR

KW - DOWN-REGULATION

KW - ABERRANT METHYLATION

KW - EPIGENETIC MECHANISM

KW - PROMOTER METHYLATION

KW - SOCIOECONOMIC-STATUS

U2 - 10.1159/000475804

DO - 10.1159/000475804

M3 - (Systematic) Review article

C2 - 28521327

SN - 1662-4246

VL - 20

SP - 100

EP - 115

JO - Public Health Genomics

JF - Public Health Genomics

IS - 2

ER -